Treatment-Resistant Depression
- 1st Edition, Volume 278 - June 28, 2023
- Editors: Cheng-Ta Li, Chih-Ming Cheng
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 7 7 8 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 7 7 9 - 3
Progress in Brain Research, Volume 278, the latest release in this ongoing serial, highlights new advances in the field with this new volume presenting interesting chapters… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProgress in Brain Research, Volume 278, the latest release in this ongoing serial, highlights new advances in the field with this new volume presenting interesting chapters on Treatment Resistant Depression overview in Adult, Treatment Resistant Depression in Children and Adolescents, Treatment Resistant Depression in Elderly, Headache and Treatment Resistant Depression, Insomnia and Treatment Resistant Depression, Tinnitus and Treatment Resistant Depression, Genetics of Antidepressant Response and Treatment Resistant Depression, Neuroinflammation via Gut-Microbiota-Brain Axis in Treatment Resistant Depression, Molecular Imaging findings for Treatment Resistant Depression, and more.
Additional sections cover Functional MRI markers for Treatment Resistant Depression: Insights and Current Challenges, Medication Strategies for Treatment Resistant Depression, Brain Stimulation for Treatment Resistant Depression, Electroconvulsive Therapy for Treatment Resistant Depression, Next Generation Antidepressants with Novel Mechanisms for Treatment Resistant Depression, Psychological aspects and Psychotherapy for Treatment Resistant Depression, and Psychiatric Rehabilitation for Treatment Resistant Depression.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in Progress in Brain Research serials
- Updated release includes the latest information on Treatment-Resistant Depression
Undergraduates, graduates, academics, and researchers in the field of neurology and brain research
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Contributors
- Preface
- Chapter 1: Overview of treatment-resistant depression
- Abstract
- 1: Rationale for defining treatment-resistant depression and solving unsolved problems
- 2: Definition of an adequate antidepressant trial and TRD
- 3: Epidemiology and poor outcomes of TRD
- 4: Different staging models for TRD
- 5: Treatment strategies for adult patients with TRD
- References
- Chapter 2: Genetics of antidepressant response and treatment-resistant depression
- Abstract
- 1: Introduction
- 2: Candidate gene association studies
- 3: Genome-wide association studies
- 4: Whole genome sequencing
- 5: Other genetic variations
- 6: Epigenetics
- 7: Discussion
- References
- Chapter 3: Neuroinflammation through the vagus nerve-dependent gut–microbiota–brain axis in treatment-resistant depression
- Abstract
- 1: Introduction
- 2: The gut–microbiota–brain axis in depression and fecal microbiota transplantation
- 3: The vagus nerve in the brain–gut axis and vagus nerve stimulation
- 4: Effects of ketamine and its enantiomers for treatment-resistant depression
- 5: Conclusions
- References
- Chapter 4: Molecular imaging findings for treatment resistant depression
- Abstract
- 1: Background
- 2: PET and SPECT findings for the neurobiology of TRD
- 3: PET and SPECT findings for the treatment of TRD
- 4: Summary of PET and SPECT findings for TRD
- 5: Future directions
- 6: Conclusions
- References
- Chapter 5: Functional MRI markers for treatment-resistant depression: Insights and challenges
- Abstract
- 1: Introduction
- 2: Functional magnetic resonance imaging and TRD
- 3: Brain connectivity and activity in TRD
- 4: Structural MRI changes in TRD
- 5: MRS and TRD
- 6: Insights, challenges, and future steps
- Conflict of interest
- References
- Chapter 6: Next generation antidepressants with novel mechanisms for treatment resistant depression
- Abstract
- 1: Traditional antidepressants in major depressive disorder treatment and their limitations
- 2: Consciousness, neuroplasticity, depression, and antidepressants (Fig. 1)
- 3: Consciousness and monoamine neurotransmitters (Fig. 1)
- 4: Altered consciousness and rapid-acting antidepressant effect: Based on the evidence of ketamine and psilocybin
- 5: Molecular and neuroimaging mechanisms of the antidepressant effect of ketamine and psilocybin (Fig. 2)
- 6: Ongoing clinical trials of rapid-acting antidepressant drug candidates
- 7: Conclusion
- References
- Chapter 7: Psychological aspects and psychotherapy for TRD
- Abstract
- 1: Psychological aspects for treatment-resistant depression
- 2: Psychotherapy for TRD
- 3: Conclusion
- References
- No. of pages: 358
- Language: English
- Edition: 1
- Volume: 278
- Published: June 28, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780323957786
- eBook ISBN: 9780323957793
CL
Cheng-Ta Li
Cheng-Ta Li is a professor at National Yang Ming Chiao Tung University and is a division chief at Taipei Veterans General Hospital. Professor Li has been devoted in the field of TRD for over 15 years. Now, he is ranked top <1% in the field of TRD with multi-disciplinary collaborations. Based on the result of Expertscape (2011-2021), he is currently ranked #< 1% (0.77%) in the world in the field of TRD and is the highest among scientists in Taiwan. This book, inviting internationally renowned experts in the field, aims to clarify unsettled issues related to TRD, to provide a better understanding about TRD, and to improve treatment efficacy for TRD.
Affiliations and expertise
Professor, National Yang Ming Chiao Tung University; Division chief, Taipei Veterans General Hospital, TaiwanCC
Chih-Ming Cheng
Dr. Chih-Ming Cheng received his psychiatric residency training and geriatric psychiatry fellowship at Taipei Veterans General Hospital(VGHTPE), Taiwan. After training, he became an attending psychiatrist in the YuanShan branch of VGHTPE and then back to VGHTPE in 2020. In academic research, he followed Prof. Cheng-Ta Li, Prof. Tung-Ping Su, and Prof. Ya-Mei Bai in the field of neuromodulation, neuroinflammation, functional neuroimaging and new antidepressant clinical trials, and Dr. Mu-Hong Chen in the field of ketamine and epidemiologic studies. His research interests are brain stimulation and epidemiology in psychiatric disorders, especially major depressive disorders. He now investigates trans-diagnostic heredity and excess mortality of psychiatric disorders and the heredity and treatment characteristics of treatment-resistant major depressive disorders by using the Taiwan national health insurance registry database, as well as the efficacy of rTMS/iTBS intervention in treatment-resistant depressed patients. He is also one of the committee experts for brain electromagnetic stimulation and treatment, Taiwan Society of Biological Psychiatry and Neuropsychopharmacology(TSBPN) and the TSBPN Working group for renewing Taiwan's recommendation of pharmacological treatment for bipolar disorder. Dr. Cheng has published about sixty peer-reviewed articles, including publications in Molecular Psychiatry, Neurology, Psychological Medicine, Psychiatry and clinical neurosciences, Allergy, and Psychiatry Research..etc.
Affiliations and expertise
Attending Psychiatrist, Division of Community and Rehabilitation Psychiatry, Taipei Veterans General Hospital, TaiwanRead Treatment-Resistant Depression on ScienceDirect